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Background: The aim of this study was to evaluate the effect of diabetes on the function and distribution of vascular 
α1-adrenoceptors in the abdominal aorta and distal mesenteric artery from streptozotocin (STZ)-induced diabetic 
rats at the level of the α1-adrenoceptor subtypes.
Methods: Diabetes was induced by a single intravenous injection of STZ (60 mg/kg) in 8 week-old male Sprague-
Dawley rats (n = 11). Age-matched normal rats (n = 14) were used as a control group. Four weeks after STZ injection, 
the tilting-induced change of the mean arterial pressure was recorded. The α1-adrenoceptor subtypes mediating the 
contractions of the distal mesenteric artery and abdominal aorta were investigated using the agonist phenylephrine 
and subtype-selective antagonists that included prazocin, 5-methylurapidil and BMY 7378. The expressions of the α1-
adrenoceptor subtypes of each artery were examined by immunofluorescence staining using the subtype selective 
antibodies.
Results: The recovery of the mean arterial pressure was delayed after positional change in the diabetic rats. 
Compared with that of the normal rats, the contractile response to phenylephrine was increased in the abdominal 
aortas and it was decreased in the distal mesenteric arteries in the diabetic rats. In addition, compared with the 
normal rats, the fluorescent intensity of all the α1-adrenoceptor subtypes was increased in the abdominal aortas and 
it was decreased in the mesenteric arteries of the diabetic rats.
Conclusions: Diabetes increased the contractility of the abdominal aorta in response to phenylephrine, yet diabetes 
decreased that of the mesenteric arteries in the STZ-induced diabetic rats. Those results are mainly based on the 
overall change of the α1-adrenoceptor, and not on the change of the specific α1-adrenoceptor subtypes. (Korean J 
Anesthesiol 2011; 60: 272-281)
Key Words:  Abdominal aorta, Alpha-1 adrenergic receptor, Diabetic complications, Experimental diabetes mellitus, 
Mesenteric artery, Streptozotocin.
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Introduction
    Diabetes affects approximately 100 million persons world  -
wide [1], and it damages the cadiovascular autonomic nerve 
fibers mainly because of the sympathetic denervation of 
the heart and the blood vessels (diabetic cardiovascular 
autonomic neuropathy) [2,3]. This change usually leads to 
arterial stiffness [4], but it leads to vasodilation in the peripheral 
arteries [5]. This vascular denervation also changes the blood 
flow responsiveness to various stimuli. For example, the 
peripheral vasoconstriction in response to sympathetic stimuli 
such as standing up or coughing is reduced [2]. Moreover, 
a previous study has shown that vasopressor support was 
needed more often during anesthesia in diabetic patients 
with autonomic dysfunction that in diabetic patients without 
autonomic dysfunction during anesthesia because the normal 
autonomic response of vasoconstriction and tachycardia 
did not completely compensate for the vasodilating effects 
of anesthesia [6]. Therefore, it has been suggested that 
preoperative cardiovascular autonomic screening of diabetic 
patients may be very useful for anesthesiologists [3]. 
    The α1-adrenoceptor plays an important role in the vascular 
sympathetic system to maintain the peripheral vascular 
resistance and the systemic arterial pressure [7-10]. Moreover, it 
is generally accepted that there are 3 functional α1-adrenoceptor 
subtypes called α1A, α1B, and α1D and that the distribution of 
those α1-adrenoceptor subtypes is different according to 
the types of arteries [11,12]. Considering these findings, the 
diabetes-induced functional and distributional changes of the 
vascular α1-adrenoceptor in different arteries would play a role 
in the pathogenesis of diabetic vascular autonomic disturbance.
    Yet to the best of our knowledge, the previous studies did not 
show consistent results about adrenergically mediated vasocon-
striction in diabetic rats [13-15]. Moreover, there has been no 
study that has focused on the diabetes-induced distributional 
change of the α1-adrenoceptor or the α1-adrenoceptor subtypes 
according to the different types of arteries.
    Therefore, we evaluated the effect of diabetes on the function 
and distribution of the vascular α1-adrenoceptor, at the level of 
α1-adrenoceptor subtypes, using the abdominal aorta and distal 
mesenteric artery in streptozotocin (STZ)-induced diabetic rats.
Materials and Methods
Animals
    Eight-week-old male rats (n = 25) were used for this study. 
All the rats were housed at 22 ± 2
oC with 40-60% humidity in a 
12/12-h light/dark cycle, and they were maintained on a diet of 
animal chow and water ad libitum. All the animal studies were 
carried out in a semi-pathogen-free barrier zone at the Institute 
for Laboratory Animal Research in Seoul National University 
Hospital in accordance with the procedure outlined in the 
Guide for the Care and Use of Laboratory Animals.
Induction of diabetes mellitus
    The rats were randomly allocated into either the control group 
(n = 14) or the diabetic group (n = 11). Diabetes was induced by 
intravenous administration of a single dose of STZ (60 mg/kg in 
citrate buffer, pH 4.5) through the tail vein. In the normal group, 
the same volume of citrate buffer was injected intravenously. 
Three days after STZ-injection, the blood glucose levels were 
measured from a drop of blood using a OneTouch Ultra
Ⓡ Blood 
Glucose Meter (LifeScan, Inc) for determining the successful 
induction of diabetes. Rats with a blood glucose level > 300 mg/
dl were considered diabetic. All the rats were maintained for 4 
weeks before intervention.
Changes in the arterial blood pressure related to tilting
    The rats’ blood glucose levels and body weight were measured 
four weeks after STZ or citrate buffer injection. For each rat, 
anesthesia was induced with sevoflurane with the rat in a 
chamber, and the anesthesia was maintained with 2 vol% 
sevoflurane. Following anesthesia, the rat was placed in a 
supine position and the four legs and upper front teeth were 
firmly fixed on a tilt board. The tail artery was cannulated with 
a 24 G catheter for continuous arterial pressure monitoring. 
To prevent the effect of postural change on measuring arterial 
pressure, the transducer was positioned at the level of the 
heart. After measuring the mean arterial pressure at the supine 
position (basal MAP), the table was vertically tilted at 45
o angle 
in the head-up direction and the MAPs at 10, 30, 60 and 120 
seconds after tilting were recorded. The changes in the MAP 
related to tilting were compared at each time point between the 
diabetic and control groups.
Preparation of vascular tissues
    After the tilting experiment, the rat was euthanized by cervical 
dislocation under the deep anesthesia and the third branch of 
the mesenteric artery and the abdominal aorta were rapidly 
removed. The arteries were placed on a Petri dish with ice-cold 
modified Krebs’ solution of the following composition (in mM): 
NaCl: 119, KCl: 4.7, MgSO4: 1.17, NaHCO3: 22, CaCl2: 1.6, HEPES: 
8, KH2PO4: 1.18, d-glucose: 5, and the arteries were cleaned 
of fat and connective tissues under a microscope (Zeiss). In 
addition, the Petri dish was kept cold by surrounding it with 
crushed ice. Following the cleaning procedure, to exclude the 274 www.ekja.org
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effect of endothelium-derived relaxing factor, the endothelium 
of the arteries was removed by gently rubbing the lumen with 
coarse silk and each artery was cut into 3-mm ring segments for 
the in vitro contractile studies.
Measurement of isomeric tension
    Each ring segment was suspended between two triangle-
shape tungsten hooks, and this was mounted in a 5 ml water- 
jacketed temperature-controlled tissue bath (Harvard Apparatus, 
Holliston, MA, USA) that contained modified Krebs’ solution. 
The lower and upper hooks were attached, respectively, to 
the bottom of the bath chamber and to a force displacement 
transducer (NP 72-4493, Harvard Apparatus, Holliston, MA, 
USA). The tissue bathing solution was gassed with a mixture of 
95% O2 and 5% CO2 (pH: 7.38-7.42, pCO2: 34-36 mmHg) and 
maintained at 37
oC. Propranolol (1 × 10
-6 M) and yohimbine 
(1 × 10
-7 M) were always included in the tissue bathing solution 
to block the β- and α2-adrenoceptors, respectively. The isometric 
contractions were recorded using an A/D converter (Powerlab
Ⓡ, 
ADInstruments, Colorado Springs, CO, USA) and they were 
analyzed by using Chart for Window Software
Ⓡ (ADInstruments, 
Colorado Springs, CO, USA).
    Following applying an initial tension of 2.0 g, which provided 
the optimum concentration-response relationships to KCl 60 
mM, the arterial strips were allowed to equilibrate for 60 min. 
When the resting tension reached a stable baseline, no attempt 
was made to adjust the tissue tension. After the equilibrium, 
tissues were primed by the addition of phenylephrine (1 × 10
-6 M) 
to the organ bath. After a steady-state contraction was achieved, 
the bath contents were replaced with drug-free buffer several 
times. The tissues were then allowed to reach baseline tension, 
and the priming procedure was repeated once more before 
constructing the concentration-response curves. This priming 
procedure reduces tissue variability in response to repeated 
agonist administration. In addition, the absence of functional 
endothelium was also confirmed by the loss of the relaxation 
response to acethylcholine (1 × 10
-6 M) in the pre-contracted 
rings with a priming dose of phenylephrine (1 × 10
-6 M) during 
the priming procedure.
Construction of the concentration-response curves
    Reproducible cumulative concentration-response curves 
were constructed by exposing each artery to increasing 
concentrations (0.5 log unit increments) of phenlyephrine 
(1 × 10
-9 to 1 × 10
-4) until a sustained maximum response 
(Emax) was observed. The concentration-response curves to 
phenylephrine were then obtained (60 min apart each) in the 
presence of four selective α1-adrenoceptor antagonists to each 
artery and the procedure was repeated with a high concentration 
of antagonists in the same preparation. The incubation time for 
the selective α1-adrenoceptor antagonists prazosin (α1; 1, 3 and 
10 × 10
-9 M), 5-methylurapidil (5-MU; α1A; 3, 10 and 30 × 10
-8 
M), and BMY 7378 (α1D; 3, 10 and 30 × 10
-8 M) was 30 min. In 
all the experiments, one preparation was run in parallel with 
the experimental tissues, but it received no antagonist, and it 
was used to determine any time-dependent changes in agonist 
sensitivity. Propranolol (1 × 10
-6 M) and yohimbine (1 × 10
-7 M) 
were always included in the tissue bathing solution to block the 
β- and α2-adrenoceptors, respectively.
Immunofluorescence staining
    After removing the vessels and cleaning the extraneous 
tissues, the arteries were cut into 2-mm rings, embedded in 
OCT compound (Tissue-Tek
Ⓡ OCT
TM Compound, Sakura 
Finetek) and quickly frozen (-50
oC in isopentane cooled with 
dry ice). The frozen blocks were cut into 5-μm sections and 
mounted on the slide. All the sections were stored at -80
oC 
until use. After warming at room temperature for 30 minutes, 
the tissue sections were fixed in iced cold acetone for 5 minutes. 
Following rinsing the sections in PBS, a blocking solution with 
10% normal donkey serum was placed on the sections and this 
was incubated for 30 minutes to block the non-specific binding 
sites of immunoglobulin. After removal of the blocking solution, 
the tissue section was incubated with the 1 : 100-diluted 
primary antibody (α1D-AR cat. no. s.c.-1475, α1B-AR cat. no. s.c.-
1476, α1A-AR cat. no. s.c.-1477; Santa Cruz Biotechnologies) 
for 60 minutes at room temperature. Following washing the 
primary antibody in PBS, fluoresceinisothiocyanate (FITC)-
conjugated donkey anti-goat IgG (1 : 100 dilution, no. s.c.-2024; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) secondary 
antibody was placed on the sections for 60 minutes in the dark 
at room temperature. After removing the secondary antibody 
by washing with PBS, mounting media was placed and a glass 
coverslip was applied. For reducing the technical errors, the 
staining was performed in one slide for same type of artery from 
two different groups. Three independent investigators observed 
the expression of the α1-adrenoceptor subtypes of each artery 
with using a fluorescence microscope (Olympus VENOX-
AHBT3, Tokyo, Japan).
Statistical analysis
    The data is presented as means ± SDs, means ± SEMs, 
number of rats or number of arterial segments. In each concen-
tration-response curve, the changes in tension related to 
increasing concentrations of phenylephrine are expressed as 
the difference of tension (g) between the basal values and the 275 www.ekja.org
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measured value in a certain concentration of phenylephrine. 
The curves were fitted to all the data by non-linear regression 
analysis using GraphPad Prism software (GraphPAD software, 
San Diego, CA, USA) to calculate the negative logarithm of the 
concentration of agonist that provokes a half-maximal response 
(pEC50 = agonist potency). The pA2 values and Schild slopes 
were calculated by the method of Arunlakshana and Schild 
[16]. Using three different concentrations of each antagonist, 
the ratios between the half-maximal concentrations (EC50) of 
phenylephrine obtained in a specific antagonist concentration 
and that obtained in its absence (the concentration ratio, R) 
were respectively calculated when the maximal amplitudes 
between the concentration-response curves in those two 
conditions were similar. The data was plotted as negative log-
concentrations of the antagonist on the x-axis vs. log (R-1) 
on the y-axis and the data was fitted as a regression line. For 
calculation purposes, the slope parameter was set to -1.0 
when it was statistically not different from unity. The x-intercept 
of the fitted regression line was the estimated pA2. pA2 is the 
estimated equilibrium dissociation constant for the specific 
antagonist and also the dose of antagonist that requires a 2-fold 
increase in the agonist concentration. Student’s t-test was used 
to determine the statistical differences between the diabetic 
and control groups. A P value < 0.05 was considered statistically 
significant.
Results
Induction of diabetes mellitus and the changes in 
arterial blood pressure related to the tilting
    The initial body weight was 242.8 ± 18.9 g for the diabetic rats 
and 244.7 ± 14.8 g for the normal rats, respectively (P = 0.79). 
Four weeks after diabetic induction, the body weight was 242.3 
± 28.0 g and the blood glucose level was 481.7 ± 110.5 mg/dl in 
Fig. 1. Time course for the change in the mean arterial pressure 
(MAP) after tilting in the streptozotocin-induced diabetic (■) and 
normal (▲) rats. Each data point represents the mean ± SD. *P < 0.01 
vs. the normal rats.
Fig. 2. Concentration-response curves for phenylephrine-induced contraction of the aorta (A) and the distal mesenteric artery (B) and as 
obtained from the streptozotocin-induced diabetic (■) and normal (▲) rats. Tension is expressed as the difference between the measured 
value and the basal value at each point. Each data point represents the mean ± SEM.
Table 1. Maximal Response (Emax) and the pEC50 Values for Phenyle-
phrine-induced Contraction of the Aorta and Distal Mesenteric 
Artery from Streptozotocin-induced Diabetic and Normal Rats
Diabetic rats Normal rats
Emax (g) pEC50 Emax (g) pEC50
Aorta
DMA
2.52 ± 0.03*
2.37 ± 0.10*
7.44 ± 0.03*
6.06 ± 0.09*
2.22 ± 0.04
2.79 ± 0.08
6.47 ± 0.05
6.74 ± 0.07
The data is presented as means ± SDs. EC50: the concentration of 
agonist that provokes a half-maximal response on the concentration-
response curve, pEC50: negative logarithm of the EC50, DMA: distal 
mesenteric artery. *P < 0.001 vs. the normal rats.276 www.ekja.org
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Fig. 3. Effects of prazosin (A), 5-methyurapidil (5-MU,) (B) and BMY 7378 (C) on the concentration-response curve of contraction in response to 
phenylephrine in the aorta and distal mesenteric arteries from the streptozotocin-induced diabetic and normal rats. Tension is expressed as the 
difference between the measured value and the basal value at each point. Each data point represents the mean ± SEM.277 www.ekja.org
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the diabetic rats. However, the body weight and blood glucose 
level in the normal rats were 428.5 ± 21.3 g and 133.1 ± 31.5 mg/
dl, respectively. The diabetic rats showed a significantly higher 
blood glucose level and a lower body weight than that of the 
normal rats (all P values < 0.001).
    After vertical tilting the table at 45° in the head-up direction, 
the recovery of the mean arterial pressure was significantly 
slower in the diabetic rats than in that in the normal rats (Fig. 1).
Concentration-response curves
    The diabetic rats showed a significantly higher Emax and 
pEC50 than that of the normal rats on the phenylephrine-
induced concentration-response curve of the abdominal aorta 
(all P values < 0.001, Table 1 and Fig. 2A). However, in the distal 
mesenteric arteries, the diabetic rats showed a lower Emax and 
pEC50 than that of the normal rats (all P values < 0.001, Table 1 
and Fig. 2B).
    Regardless of the arterial type, prazocin, 5-MU and BMY 
7378 shifted the concentration-response curve according to 
phenylephrine to the right direction for both the diabetic and 
normal rats (Fig. 3). 
    In addition, the pA2 values of prazocin, 5-MU and BMY 
7378 for inhibiting the contractile response to phenylephrine 
increased a half order of magnitude in the abdominal aorta 
from the diabetic rats, but this all decreased by a similar order 
of magnitude in the distal mesenteric arteries from the diabetic 
rats, respectively (all P < 0.001, Table 2).
Immunofluorescence staining
    The diabetic rats showed an increased fluorescent intensity 
of all the α1-adrenoceptor subtypes in the abdominal aorta (Fig. 
4A). However, in the distal mesenteric arteries, the fluorescent 
intensity of all the α1-adrenoceptor subtypes was decreased in 
Fig. 3. Continued.
Table 2. The pA2 Values Against Phenylephrine in the Aorta and 
Distal Mesenteric Artery from the Streptozotocin-induced Diabetic 
and Normal Rats
Diabetic rats Normal rats
Aorta DMA Aorta DMA
Prazocin
5-MU
BMY 7378
9.29 ± 0.08*
8.14 ± 0.07*
8.49 ± 0.01*
8.77 ± 0.06*
7.22 ± 0.17*
7.59 ± 0.12*
8.94 ± 0.04
7.79 ± 0.06
8.02 ± 0.05
9.26 ± 0.05
7.82 ± 0.04
7.96 ± 0.16
The data is expressed as means ± SDs. pA2 is theestimated 
equilibrium dissociation constant for the specific antagonist and also 
the dose of antagonist that requires a 2-fold increase in the agonist 
concentration. 5-MU: 5-methylurapidil, DMA: distal mesenteric 
artery. *P < 0.001 vs. the normal rats.278 www.ekja.org
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Fig. 4. Immunofluorescence images 
of the α1A- (A), α1B- (B) and α1D- (C) 
adrenoceptor subtypes in the abdo-
mi  nal aorta and distal mesenteric 
arteries from the streptozotocin-
induced diabetic and normal rats 
(magnification: ×200). The abdominal 
aorta showed increased fluorescent 
intensity in the diabetic rats, but the 
distal mesenteric arteries showed 
decreased fluorescent intensity in the 
diabetic rats.279 www.ekja.org
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the diabetic rats (Fig. 4B).
Discussion
    Our results showed that diabetes impaired the MAP recovery 
after positional change in rats, and that the phenylephrine-
mediated vascular contractility of diabetic rats was increased 
in the abdominal aorta and decreased in the distal mesenteric 
arteries compared with that of the normal rats. In addition, the 
diabetic abdominal aorta showed the increased fluorescent 
intensity of all the α1-adrenoceptor subtypes, but the fluorescent 
intensity of all the α1-adrenoceptor subtypes was decreased in 
the diabetic distal mesenteric arteries. However, the functional 
and distributional changes related to diabetes would be based 
on the increase or decrease of the overall α1-adrenoceptors, 
and it is not based on changes of the specific α1-adrenoceptor 
subtypes. 
    The vascular α1-adrenoceptor plays a primary role in 
main  taining the systemic arterial pressure and arteriolar 
resistance [7-10]. Since the first report of strong evidence for 
pharmacologically distinct α1-adrenoceptor subtypes in 1982 
[17], numerous studies have assessed the function, distribution 
and classification of each subtype. It is now well known that 
there are 3 functional α1-adrenoceptor subtypes (α1A, α1B, and 
α1D) corresponding to the 3-cloned α1-adrenoceptor [11]. In 
addition, recent studies have shown that the α1D-adrenoceptor 
plays a major role in the vasoconstriction of the mesenteric 
arteries [18,19] and that the α1A-adrenoceptor plays a major role 
in the vascular contraction of the distal mesenteric arteries [19]. 
Moreover, Asbún-Bojalil et al. [20] suggested that the role of 
the α1D-adrenoceptor is the most important for the contractile 
response to phenylephrine in both the abdominal and thoracic 
aortas. Therefore, in this study, to evaluate the effect of diabetes 
on the α1-adrenoceptor or the α1-adrenoceptor subtypes of the 
different types of artery, the abdominal aorta and the distal 
mesenteric artery were chosen as the conductive artery and the 
resistant artery, respectively.
    Positional change of the arterial pressure was assessed for 
testing the appropriateness of our diabetic model; 4 weeks after 
diabetic induction by STZ intravenous injection, the diabetic 
rats showed impaired recovery from the tilt-induced decrease 
in blood pressure. This phenomenon was very comparable 
with orthostatic hypotension. Considering that orthostatic 
hypotension is the most serious clinical consequence of 
diabetes-induced vascular disturbance [2], our diabetic rat 
model would be appropriate for evaluating the effect of diabetes 
on the vascular alpha 1-adrenoceptor.
    In this study, the responses of the α1-adrenoceptor to 
phenylephrine were different between the abdominal aorta and 
the mesenteric arteries according to the presence of diabetes. 
Fig. 4. Continued.280 www.ekja.org
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In the abdominal aorta, diabetes increased the Emax over 10%. 
In addition, the diabetic abdominal aorta showed an EC50 in 
a 10-times lower concentration of phenylephrine than that 
of the normal abdominal aorta. This result corresponds with 
the previous studies where diabetes increased the adrenaline-
mediated contractility in the aorta [21-24].
    However, the diabetic distal mesenteric arteries showed lower 
a Emax by over 15% and the EC50 in a 5-times higher phenyle-
phrine concentration than did the normal distal mesenteric 
arteries. This finding is incompatible with the previous studies 
where the contractility of diabetic superior mesenteric arteries 
to α1-adrenoceptor agonists was increased [25-27]. However, 
various contractile responses of the α1-adrenoceptor in the 
superior mesenteric arteries to adrenergic agonist have been 
reported [28]. It has also been suggested that those various 
results were caused not only from the different experimental 
methods, but also from the different vascular responses 
between the superior and distal mesenteric arteries [28]. In 
addition, in the study using methoxamine by Makino and 
Kamato [29], the maximum contractile response was impaired 
in the diabetic mesenteric arteries. Moreover, the results of our 
immunofluorescence staining were also in accordance with our 
different contractile responses to phenylephrine between the 
abdominal aorta and the distal mesenteric arteries. Therefore, 
we speculate that the inconsistent results might have been 
caused by the different vascular characteristics between the 
superior and distal mesenteric arteries.
    There were several limitations in this study. First, in this study, 
all the results would be based on the overall changes in the α1-
adrenoceptor. Therefore, the authors found no difference of the 
diabetes-induced functional and distributional changes of the 
specific α1-adrenoceptor subtypes. However, this is still the first 
study that has evaluated the relationship between diabetes and 
the α1-adrenoceptor subtypes. Second, the distribution of the 
α1-adrenoceptor subtypes was not quantified using Western 
blotting. In our experiments, we failed to get consistent results 
for Western blotting. Therefore, we could not quantify our 
results. However, consider a recent report that used commercial 
antibodies for the α1-adrenoceptor subtypes [30], and that 
inconsistency might have been caused by the limitations of 
the commercial antibodies. Moreover, that previous report 
has also suggested that competition radio-ligand binding is 
the only reliable approach to quantify the α1-adrenoceptor 
subtype proteins [30]. More studies are needed to overcome the 
limitations of our study. 
    In conclusion, progressed diabetes increased the contractile 
response to phenylephrine in the abdominal aorta, but it 
decreased the contractile response in the mesenteric arteries 
in STZ-induced diabetic rats. Those results were caused by the 
overall change in the α1-adrenoceptor, and not from the change 
in the specific α1-adrenoceptor subtypes. Our results may be 
helpful to understand one of the complex pathophysiologies 
of diabetic cardiovascular autonomic neuropathy, and this 
is a very common and serious complication that clinical 
anesthesiologists are obligated to deal with.
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